NCT02464007 - Study of rSIFN-co for Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions

Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor

Interventions

BIOLOGICAL

rSIFN-co

Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.

Trial Locations (4)

55101

HealthPartners Institute, Saint Paul

60612

Rush University Medical Center, Chicago

University of Illinois, Chicago, Chicago

85054

Mayo Clinic, Phoenix